Last reviewed · How we verify

tree 12 SQ-Bet

Clinique Spécialisée en Allergies de la Capitale · FDA-approved active Small molecule

Tree 12 SQ-Bet is an allergen immunotherapy product that desensitizes patients to tree pollen allergens through gradual exposure.

Tree 12 SQ-Bet is an allergen immunotherapy product that desensitizes patients to tree pollen allergens through gradual exposure. Used for Allergic rhinitis and/or allergic asthma caused by tree pollen allergens.

At a glance

Generic nametree 12 SQ-Bet
Also known asITULATEK
SponsorClinique Spécialisée en Allergies de la Capitale
Drug classAllergen immunotherapy (sublingual tablet)
TargetTree pollen allergens (IgE cross-linking epitopes)
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhaseFDA-approved

Mechanism of action

This is a sublingual immunotherapy (SLIT) tablet containing standardized tree pollen allergen extract, likely from multiple tree species. It works by inducing immune tolerance through repeated sublingual administration, shifting the immune response from Th2-mediated allergic reactions toward Th1/Treg-mediated tolerance. The mechanism involves gradual upregulation of regulatory T cells and IL-10 production, reducing allergic symptoms upon natural allergen exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: